Bring your portfolio to life with these top healthcare shares

One area of the market which I’m particularly bullish on in the long-term is the healthcare sector.

Due to factors including increased chronic disease burden, population growth, ageing populations, and better treatments, I expect demand for healthcare products and services will grow strongly over the next couple of decades.

With that in mind, here are three top healthcare shares that I would buy today:

CSL Limited (ASX: CSL)

If you only have room for one healthcare share in your portfolio I would make it CSL. Although the global biotech company’s shares have risen strongly over the last 12 months, I believe this has been more than deserved after its blockbuster first-half result and guidance for the full-year. This year CSL expects to achieve net profit after tax in the range of US$1,680 and US$1,710 million. Which will be growth of almost 28% year-on-year at the top end of its guidance. As well as a strong performance from its core business, the emergence of its Seqirus influenza business was a key highlight and source of growth during the half. I expect more of the same in the second-half and the foreseeable future.

Pro Medicus Limited (ASX: PME)

Pro Medicus is a healthcare technology company that I think has a bright future ahead of it. The main attraction to the company for me is its increasingly popular Visage 7. This impressive piece of software provides radiologists and referring physicians with fast server-side rendered images streamed via an intelligent thin-client viewer. This allows its users to have a customised protocol-driven workflow to natively view multi-dimensional imagery and a patient’s complete imaging history. It will come as no surprise to learn that some highly respected healthcare institutions in the U.S. have signed multi-year agreements for the software in the last 12 months.

Volpara Health Technologies Ltd (ASX: VHT)

Another up and coming healthcare technology company is Volpara Health Technologies. The New Zealand-based company specialises in breast imaging analytics and analysis software. Its software is regulatory cleared (FDA, CE, TGA), patent protected, clinically validated, used in 36 countries, and has over 273 supporting science publications. On Thursday the company advised that its market share has grown to 3.7% in the United States and reiterated its target of a 9% share by the end of FY 2019. It if achieves this it is likely to lead to another significant jump in its annualised recurring revenues. In FY 2018 they rose an impressive 223%.

The ASX healthcare small cap up 285% with no sign of stopping...

One Australian company has developed a state of the art device that's revolutionizing hospitals all over the world. Even better, this device is so profitable that the company rakes in 90% margins. That's a lot of cash. So no wonder the stock's up 285% since 2008 – with no signs of stopping...

To discover the name and code, simply click the link below. You'll discover our expert's #1 medical technology pick... and you can decide for yourself whether to get invested today.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended PRO Medicus Ltd. and VOLPARA FPO NZ. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…


The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!